283 related articles for article (PubMed ID: 33089483)
21. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
22. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.
Lamichhane N; Melas N; Bergqvist V; ; Ekholm NP; Olén O; Ludvigsson JF; Hjortswang H; Marsal J; Eriksson C; Halfvarson J
Dig Dis Sci; 2024 Jun; 69(6):2175-2183. PubMed ID: 38637457
[TBL] [Abstract][Full Text] [Related]
23. Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting.
Hemming-Harlo M; Merras-Salmio L; Nikkonen A; Kolho KL
Eur J Pediatr; 2024 Jan; 183(1):313-322. PubMed ID: 37878072
[TBL] [Abstract][Full Text] [Related]
24. Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting.
Kolehmainen S; Ylisaukko-Oja T; Jokelainen J; Koivusalo M; Jokiranta TS; Sipponen T
Scand J Gastroenterol; 2021 Aug; 56(8):906-913. PubMed ID: 34154506
[TBL] [Abstract][Full Text] [Related]
25. Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease.
Fernandes SR; Rodrigues IC; Serrazina J; Botto IA; Bernardo S; Gonçalves AR; Valente A; Moura Santos P; Correia LA; Marinho RT
Scand J Gastroenterol; 2022 Oct; 57(10):1202-1208. PubMed ID: 35599574
[TBL] [Abstract][Full Text] [Related]
26. Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.
Buer LCT; Moum BA; Cvancarova M; Warren DJ; Bolstad N; Medhus AW; Høivik ML
Scand J Gastroenterol; 2019 Jan; 54(1):41-48. PubMed ID: 30650312
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.
Restellini S; Khanna R; Afif W
Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272
[TBL] [Abstract][Full Text] [Related]
28. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
Singh S; Dulai PS; Vande Casteele N; Battat R; Fumery M; Boland BS; Sandborn WJ
Aliment Pharmacol Ther; 2019 Oct; 50(8):848-857. PubMed ID: 31483522
[TBL] [Abstract][Full Text] [Related]
29. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumab.
Ansari M; Glassner K; Irani M; Saleh A; Wang L; Ezeana C; Wong S; Perry C; Abraham B
J Dig Dis; 2024 Feb; 25(2):91-99. PubMed ID: 38599667
[TBL] [Abstract][Full Text] [Related]
31. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
Moens A; Verstockt B; Alsoud D; Sabino J; Ferrante M; Vermeire S
Inflamm Bowel Dis; 2022 Aug; 28(8):1135-1142. PubMed ID: 34751766
[TBL] [Abstract][Full Text] [Related]
32. Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations.
Bian S; Van den Berghe N; Vandersmissen L; Tops S; Vermeire S; Ferrante M; Gils A; Thomas D
J Pharm Biomed Anal; 2020 Jun; 185():113224. PubMed ID: 32151929
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE).
Reenaers C; Cremer A; Dewit O; De Vroey B; Van Moerkercke W; Bossuyt P; Muls V; Imschoot J; Block S; Hantson A; Van Hootegem P
Acta Gastroenterol Belg; 2020; 83(1):15-23. PubMed ID: 32233267
[TBL] [Abstract][Full Text] [Related]
34. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.
Feagan BG; Schwartz D; Danese S; Rubin DT; Lissoos TW; Xu J; Lasch K
J Crohns Colitis; 2018 Apr; 12(5):621-626. PubMed ID: 29471381
[TBL] [Abstract][Full Text] [Related]
36. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
37. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients.
Schulze H; Esters P; Hartmann F; Stein J; Christ C; Zorn M; Dignass A
Scand J Gastroenterol; 2018 Jun; 53(6):670-676. PubMed ID: 29560811
[TBL] [Abstract][Full Text] [Related]
38. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.
Guidi L; Pugliese D; Panici Tonucci T; Bertani L; Costa F; Privitera G; Tolusso B; Di Mario C; Albano E; Tapete G; Gremese E; Papa A; Gasbarrini A; Rapaccini GL; Armuzzi A
United European Gastroenterol J; 2019 Nov; 7(9):1189-1197. PubMed ID: 31700632
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
Kopylov U; Ron Y; Avni-Biron I; Koslowsky B; Waterman M; Daher S; Ungar B; Yanai H; Maharshak N; Ben-Bassat O; Lichtenstein L; Bar-Gil Shitrit A; Israeli E; Schwartz D; Zittan E; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
Inflamm Bowel Dis; 2017 Mar; 23(3):404-408. PubMed ID: 28178003
[TBL] [Abstract][Full Text] [Related]
40. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.
Hanžel J; Sever N; Ferkolj I; Štabuc B; Smrekar N; Kurent T; Koželj M; Novak G; Compernolle G; Tops S; Gils A; Drobne D
United European Gastroenterol J; 2019 Jul; 7(6):741-749. PubMed ID: 31316778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
